Protalex

CLINICAL TRIAL RESULTS

Protalex received United States Food and Drug Administration approval of its Investigative New Drug application for PRTX-100 in the rheumatoid arthritis indication in September 2005. A Phase I clinical trial conducted in 36 healthy volunteers was completed in mid-2006.

 

contents

• Overview
• PRTX-100 for Idiopathic Thrombocytopenic Purpura
  • About Idiopathic
    Thrombocytopenic Purpura
  • Description and status
  • Publications
• PRTX-100 for Rheumatoid
  Arthritis
  • About Rheumatoid
    Arthritis
  • Description and status
  • Clinical trial results
  • Publications